Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $741000.0.

  • ImmunityBio's Capital Expenditures fell 5841.75% to $741000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 6030.47%. This contributed to the annual value of $6.9 million for FY2024, which is 7747.84% down from last year.
  • Per ImmunityBio's latest filing, its Capital Expenditures stood at $741000.0 for Q3 2025, which was down 5841.75% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Capital Expenditures ranged from a high of $27.3 million in Q1 2022 and a low of -$2.1 million during Q2 2023
  • Moreover, its 5-year median value for Capital Expenditures was $7.1 million (2021), whereas its average is $8.0 million.
  • Per our database at Business Quant, ImmunityBio's Capital Expenditures skyrocketed by 182997.28% in 2021 and then tumbled by 11303.53% in 2023.
  • Over the past 5 years, ImmunityBio's Capital Expenditures (Quarter) stood at $10.4 million in 2021, then surged by 81.98% to $18.9 million in 2022, then plummeted by 57.98% to $8.0 million in 2023, then crashed by 73.46% to $2.1 million in 2024, then crashed by 64.9% to $741000.0 in 2025.
  • Its Capital Expenditures stands at $741000.0 for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.